1. Safety and PK of Subcutaneous GS-6207, a Novel HIV-1 Capsid Inhibitor

2. Disclosure

3. Acknowledgements

4. Introduction

5. GS-6207: First-in-Class HIV Capsid Inhibitor

6. GS-6207: First-in-Class HIV Capsid Inhibitor

7. GS-6207: Overview

8. GS-6207 First-In-Human Phase 1 Study

9. GS-6207 First-In-Human Phase 1 Study: Methods

10. Results Subject Enrollment and Demographics

11. Results Safety

12. Results Sustained GS-6207 Exposure Following Subcutaneous Injection

13. Results Sustained GS-6207 Exposure Following Subcutaneous Injection

14. Results Sustained Delivery Supports Dosing Interval of at least 12 Weeks

15. Conclusions